Malcisbo Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 8
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $430K
Latest Deal Amount
  • Investors
  • 4

Malcisbo General Information

Description

Developer of carbohydrate-based vaccines designed to target bacterial diseases targeting animal health, human food safety and zoonotic diseases. The company offers vaccines against bacterial and parasitic diseases like, Campylobacter infection, Actinobacillus pleuropneumoniae infection, Haemonchus infection and Heartworm and Hookworm infection, enabling medical professionals to target unmet needs in human and veterinary medicine

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Primary Office
  • Wagistrasse 27a
  • 8952 Schlieren
  • Switzerland
+41 044 000 00 00

Malcisbo Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Malcisbo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 23-May-2019 $430K 00.000 00.000 Completed Startup
6. Later Stage VC 14-Mar-2018 00.000 00.00 00.000 Completed Startup
5. Later Stage VC 11-Sep-2017 00000 00.000 00.000 Completed Startup
4. Later Stage VC 19-Jan-2016 00.00 00.000 00.000 Completed Startup
3. Grant 00.000 00.000 Completed Startup
2. Seed Round 19-Sep-2011 $4.34M $4.46M 00.000 Completed Startup
1. Accelerator/Incubator 10-Jun-2009 $119K $119K Completed Startup
To view Malcisbo’s complete valuation and funding history, request access »

Malcisbo Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference 000,000 00.00 00.00 00 00.00 0.000
Preference 000,000 00.00 00.00 00 00.00 00.000
Preference 140,416 $2.46 $2.46 1x $2.46 18.13%
Preference 140,416 $25.46 $25.46 1x $25.46 18.13%
To view Malcisbo’s complete cap table history, request access »

Malcisbo Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of carbohydrate-based vaccines designed to target bacterial diseases targeting animal health, human food safet
Biotechnology
Schlieren, Switzerland
8 As of 2020
00.000
0.000 0000-00-00
0000000000 0 00.000

00000000

cididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamc
0000 000000000
Schlieren, Switzerland
00 As of 0000
000.00
00000000000 000.00

00000000

sse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000 000000000
Schlieren, Switzerland
00 As of 0000
000.00
0000 0000-00-00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Malcisbo Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Redbiotec Venture Capital-Backed Schlieren, Switzerland 00 000.00 00000000000 000.00
0000000000 Formerly VC-backed Schlieren, Switzerland 00 000.00 000000&0 000.00
0000000 Venture Capital-Backed Wuppertal, Germany 00 000.00 0000000000 000.00
0000 Accelerator/Incubator Backed Lausanne, Switzerland 00 000.00 0000000000 000.00
To view Malcisbo’s complete competitors history, request access »

Malcisbo Executive Team (7)

Name Title Board Seat Contact Info
Lino Camponovo Co-Founder, Chief Executive Officer & Chief Medical Officer
Christine Neupert Ph.D Chief Scientific Officer & Deputy CEO
Marc Baer Ph.D Chairman & President
Markus Aebi Ph.D Co-Founder & Advisor
Benjamin Wilhelm Ph.D Vice Chairman & Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

Malcisbo Board Members (5)

Name Representing Role Since
Benjamin Wilhelm Ph.D Malcisbo Vice Chairman & Board Member 000 0000
David Gerber Ph.D Self Board Member 000 0000
Marc Baer Ph.D Malcisbo Chairman & President 000 0000
You’re viewing 3 of 5 board members. Get the full list »

Malcisbo Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Malcisbo Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Redalpine Venture Partners Venture Capital Minority 000 0000 000000 0
Zürcher Kantonalbank Corporation Minority 000 0000 000000 0
StartAngels Network Angel Group Minority 000 0000 000000 0
Venture Kick Accelerator/Incubator Minority 000 0000 000000 0
To view Malcisbo’s complete investors history, request access »